CD274 and neoplasm: If this conclusion is true, the anti-PD-1 antibody possesses the ability to not only inhibit the PD-1/PD-L1 axis [92] but also to deplete Treg, and it could explain why the PD-L1 expression on the surface of the tumor does not directly correlate with the response of the anti-PD-1 antibody therapy or why the efficacy of the anti-PD-1 antibody is superior to that of the anti-PD-L1 antibody [93] (though the efficacy of the anti-PD-1 and anti-PD-L1 antibodies is also controversial [94,95]).